# Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

> **NCT03971617** · PHASE2,PHASE3 · TERMINATED · sponsor: **Stony Brook University** · enrollment: 2 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Hydrogen
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT03971617
- **Lead sponsor:** Stony Brook University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-29
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-04-29
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Insufficient enrollment to answer research question
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971617, "Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03971617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*